JNJ
JOHNSON & JOHNSON
$237.00
+2.08%
$558.9B
No data for this timeframe.
Vol
Market Cap$558.9B
Cap SizeMega Cap
Analyst ConsensusBuy (68%)
Inst. Holders15 funds
Inst. Value$84.4B
Inst. Activity2 buys / 3 sells
Insider Activity0B / 1S
Insider Net $-$324.8K
Reddit Sentiment75° Bullish
SEC Reports10
Congressional9 trades
Recent Activity
Jul 14, 2026
earnings_calendar
JNJ Q2 2026 Earnings After Market Close — 2026-07-14
EPS est: $2.91 | Rev est: $25.3B
Jun 6, 2026
SEC
Freedom Broker downgrades JNJ to Hold — PT $190 (-18.4%)
ANALYST-DOWNGRADE — Impact 3/10
May 13, 2026
SEC
Leerink Partners double upgrades to Outperform — PT $265 (+18%)
ANALYST-UPGRADE — Impact 3/10
May 7, 2026
SEC
Freedom Broker double downgrades [TICKER] to Hold — PT $190, implying 15% downside from $224.62
ANALYST-DOWNGRADE — Impact 5/10
May 1, 2026
Insider
REED JOHN C sold 25,255 shares
EVP, Innovative Medicine, R&D @ $0.00 ($0.00)
May 1, 2026
Insider
REED JOHN C sold 11,002 shares
EVP, Innovative Medicine, R&D @ $229.85 ($2.5M)
May 1, 2026
Insider
REED JOHN C sold 25,255 shares
EVP, Innovative Medicine, R&D @ $0.00 ($0.00)
Inst.
NORGES BANK — NEW
33,459,884 shares ($6.9B)
Price Targets
$252.87
+6.7% upside
Buy
Current $237.00
Low $155.00
Median $260.00
High $285.00
23 analysts
$155.00
$285.00
Analyst Ratings
7Strong Buy
14Buy
10Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Leerink Partners | UPGRADE | Market Perform → Outperform |
| Apr 15, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Apr 15, 2026 | Stifel | MAINTAIN | Hold → Hold |
| Apr 15, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.85 ▲ +0.5% | $2.65 — $3.00 | 3% YoY | 16 |
| Next Q | $3.02 | $2.96 — $3.21 | 8% YoY | 16 |
| Current FY | $11.57 | $11.45 — $11.82 | 7% YoY | 24 |
| Next FY | $12.72 | $12.07 — $13.47 | 10% YoY | 24 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $49.7B | — |
| MORGAN STANLEY | $9.6B | — |
| NORGES BANK | $6.9B | NEW |
| BANK OF AMERICA CORP | $5.9B | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.9B | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | REED JOHN | M | $0.00 |
| May 1, 2026 | REED JOHN | F | $2.5M |
| May 1, 2026 | REED JOHN | M | $0.00 |
| Apr 23, 2026 | Beckerle Mary | A | $0.00 |
| Apr 23, 2026 | Doudna Jennifer | A | $0.00 |
Reddit Sentiment
75°▲
Bullish
Bearish
Neutral
Bullish
Congressional Trades
5 members: 3 buys, 6 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $15,001 - $50,000 |
| Thomas Kean | R | SELL | $1,001 - $15,000 |
| Rich McCormick | R | SELL | $1,001 - $15,000 |
15 institutional holders with $84.4B total value (408,056,066 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, NORGES. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 240,349,660 | $49.7B | 58.9% | — |
| 2 | MORGAN STANLEY | 46,325,589 | $9.6B | 11.4% | — |
| 3 | NORGES BANK | 33,459,884 | $6.9B | 8.2% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 28,333,601 | $5.9B | 6.9% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19,034,302 | $3.9B | 4.7% | NEW |
| 6 | FMR LLC | 18,776,671 | $3.9B | 4.6% | ADD +39.7% |
| 7 | WELLS FARGO & COMPANY/MN | 18,523,844 | $3.8B | 4.5% | — |
| 8 | YACKTMAN ASSET MANAGEMENT LP | 1,252,646 | $259.2M | 0.3% | — |
| 9 | Cullen Capital Management, LLC | 1,159,046 | $239.9M | 0.3% | — |
| 10 | Mawer Investment Management Ltd. | 415,882 | $86.1M | 0.1% | NEAR_EXIT -79.6% |
| 11 | Tweedy, Browne Co LLC | 236,075 | $48.9M | 0.1% | TRIM -44.2% |
| 12 | TWO SIGMA INVESTMENTS, LP | 95,659 | $19.8M | 0.0% | NEAR_EXIT -90.5% |
| 13 | ARIEL INVESTMENTS, LLC | 43,260 | $9.0M | 0.0% | ADD +66.4% |
| 14 | DODGE & COX | 20,947 | $4.3M | 0.0% | — |
| 15 | Olstein Capital Management, L.P. | 29,000 | $6.0K | 0.0% | TRIM -40.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 33,459,884 | — | $6.9B | 2025-Q4 |
| FMR LLC | ADD | 13,443,427 | 18,776,671 | +39.7% | $3.9B | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 1,010,787 | 95,659 | -90.5% | $19.8M | 2025-Q4 |
| Olstein Capital Management, L.P. | TRIM | 48,500 | 29,000 | -40.2% | $6.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 306,747 | 0 | -100.0% | $0.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 176,992 | 1,010,787 | +471.1% | $187.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 883,190 | 306,747 | -65.3% | $56.9M | 2025-Q3 |
| ARIEL INVESTMENTS, LLC | ADD | 31,163 | 51,854 | +66.4% | $9.6M | 2025-Q3 |
| NORGES BANK | EXIT | 31,929,124 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 31,929,124 | — | $4.9B | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 202,563 | 883,190 | +336.0% | $134.9M | 2025-Q2 |
| Tweedy, Browne Co LLC | TRIM | 438,271 | 244,713 | -44.2% | $37.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 23,957 | 176,992 | +638.8% | $27.0M | 2025-Q2 |
| Tweedy, Browne Co LLC | TRIM | 1,080,471 | 438,271 | -59.4% | $72.7M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 921,499 | 202,563 | -78.0% | $33.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 63,768 | 23,957 | -62.4% | $4.0M | 2025-Q1 |
| NORGES BANK | EXIT | 30,355,672 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 921,499 | — | $133.3M | 2024-Q4 |
| Mawer Investment Management Ltd. | NEAR_EXIT | 2,503,774 | 510,936 | -79.6% | $73.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 17,639,368 | — | $2.9B | 2024-Q3 |
22 unique insiders with 1 transactions. Net insider value: -$324.8K ($0.00 bought, $324.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | 25,255 | $0.00 | $0.00 |
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | F | 11,002 | $229.85 | $2.5M |
| May 1, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | 25,255 | $0.00 | $0.00 |
| Apr 23, 2026 | Beckerle Mary C | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | Doudna Jennifer A | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | HEWSON MARILLYN A | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | Johnson Paula A | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | Joly Hubert | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | McClellan Mark B. | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | MORIKIS JOHN G | Director | A | 1,540 | $0.00 | $0.00 |
| Apr 23, 2026 | Pinto Daniel E | Director | A | 1,712 | $0.00 | $0.00 |
| Apr 23, 2026 | WEINBERGER MARK A | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | West Nadja | Director | A | 975 | $0.00 | $0.00 |
| Apr 23, 2026 | Woods Eugene A. | Director | A | 975 | $0.00 | $0.00 |
| Mar 10, 2026 | Woods Eugene A. | Director | A | 154.869 | $242.14 | $37.5K |
| Mar 10, 2026 | HEWSON MARILLYN A | Director | A | 206.492 | $242.14 | $50.0K |
| Mar 10, 2026 | Pinto Daniel E | Director | A | 129.058 | $242.14 | $31.3K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | M | 4,075 | $115.67 | $471.4K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | M | 4,075 | $0.00 | $0.00 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | SELL | 1,322 | $245.66 | $324.8K |
| Feb 9, 2026 | Duato Joaquin | CEO and Chairman of the Board | A | 73,054 | $0.00 | $0.00 |
| Feb 9, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | 13,706 | $0.00 | $0.00 |
| Feb 9, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | A | 13,706 | $0.00 | $0.00 |
| Feb 9, 2026 | Mulholland Kristen | EVP, Chief HR Officer | A | 3,602 | $0.00 | $0.00 |
| Feb 9, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | A | 4,378 | $0.00 | $0.00 |
| Feb 9, 2026 | Swanson James D. | EVP, CIO | A | 9,412 | $0.00 | $0.00 |
| Feb 9, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | 27,412 | $0.00 | $0.00 |
| Feb 9, 2026 | Wolk Joseph J | Exec VP, CFO | A | 37,463 | $0.00 | $0.00 |
| Feb 9, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | 8,594 | $0.00 | $0.00 |
| Feb 9, 2026 | Decker Robert J | VP Corporate Controller | A | 2,741 | $0.00 | $0.00 |
| Feb 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | 5,625 | $101.87 | $573.0K |
| Feb 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | 3,335 | $239.99 | $800.4K |
| Feb 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | 5,625 | $101.87 | $573.0K |
| Feb 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | 38,945 | $101.87 | $4.0M |
| Feb 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | 27,270 | $239.99 | $6.5M |
| Feb 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | 38,945 | $101.87 | $4.0M |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | 15,571 | $101.87 | $1.6M |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | 10,335 | $239.99 | $2.5M |
| Feb 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | 15,571 | $101.87 | $1.6M |
| Feb 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | 8,921 | $129.51 | $1.2M |
| Feb 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | 6,226 | $237.90 | $1.5M |
| Feb 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | 8,921 | $129.51 | $1.2M |
| Mar 4, 2025 | HEWSON MARILLYN A | Director | A | 75.256 | $166.10 | $12.5K |
10 SEC filing reports analyzed. Sentiment: 3 bullish, 2 bearish, 1 mixed, 4 neutral. Avg impact: 4.1/10.
BEARISH
ANALYST-DOWNGRADE
3/10
Freedom Broker downgrades JNJ to Hold — PT $190 (-18.4%)
Jun 6, 2026
BEARISH
ANALYST-DOWNGRADE
5/10
Freedom Broker double downgrades [TICKER] to Hold — PT $190, implying 15% downside from $224.62
May 7, 2026
BULLISH
ANALYST-UPGRADE
3/10
Leerink Partners double upgrades to Outperform — PT $265 (+18%)
May 13, 2026
BULLISH
ANALYST-UPGRADE
5/10
Morgan Stanley upgrades JNJ to Overweight — PT $262 (+16.3%)
May 31, 2026
NEUTRAL
COURT-RULING
1/10
The Ninth Circuit affirmed the district court's dismissal of a product liability case against Jansse
May 20, 2026
NEUTRAL
COURT-RULING
3/10
Janssen (JNJ) and Tolmar jointly moved to remand patent infringement appeals after reaching a settle
May 5, 2026
BULLISH
8-K
8/10
Johnson & Johnson reported Q1 2026 earnings with adjusted EPS of $2.70, narrowly beating consensus o
Apr 14, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable
Mar 30, 2026
NEUTRAL
DEFA14A
3/10
Johnson & Johnson filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting.
Mar 11, 2026
MIXED
INST-CLUSTER
7/10
In Q4 2025, Johnson & Johnson saw a mixed institutional cluster: two major institutions—Fidelity and
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (68% buy). Based on 31 analysts: 7 strong buy, 14 buy, 10 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$252.87 mean target
+6.7% upside
Buy (2.00)
$155.00 Low
$285.00 High
| Metric | Value |
|---|---|
| Current Price | $237.00 |
| Target Low | $155.00 |
| Target Mean | $252.87 |
| Target Median | $260.00 |
| Target High | $285.00 |
| # Analysts | 23 |
| Recommendation | Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.85 | $2.65 | $3.00 | 3.0% | +0.5% | 1↑ 1↓ | $25.0B | 5.3% | 16 |
| Next Q 2026-09-30 |
$3.02 | $2.96 | $3.21 | 8.0% | +0.2% | 1↑ 1↓ | $25.2B | 5.2% | 16 |
| Current FY 2026-12-31 |
$11.57 | $11.45 | $11.82 | 7.3% | -0.0% | 1↑ 1↓ | $100.9B | 7.1% | 24 |
| Next FY 2027-12-31 |
$12.72 | $12.07 | $13.47 | 9.9% | +0.1% | 1↑ 1↓ | $107.3B | 6.3% | 24 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.853 | |
| 7d ago | $2.853 | |
| 30d ago | $2.839 | +0.015 |
| 60d ago | $2.884 | -0.031 |
| 90d ago | $2.883 | -0.029 |
17 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Apr 15, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 15, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Apr 15, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 30, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Mar 19, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 17, 2026 | HSBC | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Feb 3, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 28, 2026 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Jan 27, 2026 | Freedom Capital Markets | MAINTAIN | Hold | Hold |
| Jan 27, 2026 | Freedom Broker | MAINTAIN | Hold | Hold |
| Jan 23, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Jan 22, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 22, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 22, 2026 | Scotiabank | MAINTAIN | Sector Outperform | Sector Outperform |
| Jan 22, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Jan 9, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Dec 30, 2025 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 19, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Dec 12, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 14 | 10 | 0 | 0 | 68% | |
| May 1, 2026 | 6 | 14 | 12 | 0 | 0 | 63% | |
| Apr 1, 2026 | 6 | 14 | 12 | 0 | 0 | 63% | |
| Mar 1, 2026 | 6 | 13 | 13 | 0 | 0 | 59% | |
| Feb 1, 2026 | 6 | 13 | 13 | 0 | 0 | 59% | |
| Jan 1, 2026 | 6 | 12 | 14 | 0 | 0 | 56% | |
| Dec 1, 2025 | 6 | 13 | 13 | 0 | 0 | 59% | |
| Nov 1, 2025 | 6 | 12 | 13 | 0 | 0 | 58% |
Strong BuyBuyHoldSellStrong Sell
5 members of Congress traded this stock: 3 buys, 6 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $15,001 - $50,000 | Johnson & Johnson | May 13, 2026 (31d) |
| Mar 26, 2026 | Thomas Kean Jr | R | HOUSE | SELL | $1,001 - $15,000 | Johnson & Johnson | Apr 14, 2026 (20d) |
| Mar 19, 2026 | Rich McCormick | R | HOUSE | SELL | $1,001 - $15,000 | Johnson & Johnson | Apr 8, 2026 (21d) |
| Mar 19, 2026 | Rich McCormick | R | HOUSE | SELL | $1,001 - $15,000 | Johnson & Johnson | Apr 8, 2026 (21d) |
| Mar 19, 2026 | John Boozman | R | SENATE | SELL | $1,001 - $15,000 | Johnson & Johnson | Apr 14, 2026 (27d) |
| Mar 10, 2026 | Lloyd Doggett | D | HOUSE | BUY | $1,001 - $15,000 | Johnson & Johnson | Apr 8, 2026 (30d) |
| Mar 6, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Johnson & Johnson | Apr 9, 2026 (35d) |
| Mar 6, 2026 | Ro Khanna | D | HOUSE | SELL | $1,001 - $15,000 | Johnson & Johnson | Apr 9, 2026 (35d) |
| Jan 23, 2026 | Thomas Kean Jr | R | HOUSE | SELL | $15,001 - $50,000 | Johnson & Johnson | Feb 20, 2026 (29d) |
75°
Bullish
Bearish
Neutral
Bullish
6 mentions
5 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Top Dividend Stocks for 2025: 6 Picks Paying 3%+
▲ 1
💬 0
⚡ 0.5
JNJ still worth it?
▲ 1
💬 0
⚡ 0.5
JNJ still worth it?
▲ 1
💬 0
⚡ 0.5
Jul 14, 2026
earnings_calendar
JNJ Q2 2026 Earnings After Market Close — 2026-07-14
EPS est: $2.91 | Rev est: $25.3B
Jun 9, 2026
Clinical Trial
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
Phase Phase 3 — TERMINATED
Jun 9, 2026
Clinical Trial
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Phase Phase 3 — COMPLETED
Jun 5, 2026
Clinical Trial
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Phase Phase 2 — COMPLETED
Jun 5, 2026
Clinical Trial
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Phase Phase 3 — COMPLETED
Jun 5, 2026
clinical_trial_readout
Results Pending: Teclistamab (Phase 2) — Completed 53d ago
Trial: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Janssen Pharmaceutical K.K.
Phase: Phase
Jun 4, 2026
Clinical Trial
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Phase Phase 2 — TERMINATED
Jun 2, 2026
clinical_trial_readout
T-90d Trial Readout: Cilta-cel (Phase 2)
Trial: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Sponsor: Janssen Researc
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: Rilpivirine (Phase 2)
Trial: A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediat
May 22, 2026
short_volume
Short Volume: JNJ — 55.5% short (1.1M / 2.0M)
Short: 1,120,658 | Exempt: 2,751 | TRF Vol: 2,019,459 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
clinical_trial_readout
T-90d Trial Readout: Rilpivirine (Phase 2)
Trial: A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediat
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: JNJ-68284528 (Phase 2)
Trial: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants W
May 18, 2026
short_volume
Short Volume: JNJ — 59.3% short (1.6M / 2.8M)
Short: 1,641,615 | Exempt: 433 | TRF Vol: 2,766,276 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: JNJ — 7.4M shares, 138,357 trades
Week starting 2026-05-18. Total ATS volume: 7,356,146 shares across 138,357 trades.
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: JNJ-68284528 (Phase 2)
Trial: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants W
May 11, 2026
dark_pool
Dark Pool: JNJ — 6.5M shares, 137,449 trades
Week starting 2026-05-11. Total ATS volume: 6,520,451 shares across 137,449 trades.
May 7, 2026
short_interest
FTD: JNJ — 5,684 shares ($1.3M) failed to deliver
Settlement: 20260507, Price: $224.62, FTD Value: $1,276,740.08, JOHNSON AND JOHNSON
May 6, 2026
clinical_trial_readout
T-90d Trial Readout: JNJ-68284528 (Phase 2)
Trial: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants W
May 4, 2026
dark_pool
Dark Pool: JNJ — 6.9M shares, 148,125 trades
Week starting 2026-05-04. Total ATS volume: 6,941,848 shares across 148,125 trades.
May 1, 2026
clinical_trial_readout
Results Pending: Milvexian (Phase 3) — Completed 84d ago
Trial: A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor: Janssen Research & Development, LLC
Phase: Phase 3 | Compl
Apr 20, 2026
FDA
CONCERTA
WARNING: ABUSE, MISUSE, AND ADDICTION CONCERTA has a high potential for abuse and misuse, which can lead to the development of a substance use disorde
Mar 30, 2026
Enforcement
3:25-cv-06161 SNYDER et al v. JANSSEN PHARMACEUTICALS, INC. et al
Court ruling from United States District Court for the District of New Jersey. Docket: N/A
Mar 24, 2026
FDA
XARELTO
Supplemental Approval — Labeling — RIVAROXABAN — FOR SUSPENSION — ORAL
Mar 24, 2026
FDA
XARELTO
Supplemental Approval — Labeling — RIVAROXABAN — FOR SUSPENSION — ORAL
Mar 24, 2026
FDA
XARELTO
Supplemental Approval — Labeling — RIVAROXABAN — FOR SUSPENSION — ORAL